Last updated: 25 January 2023 at 4:31pm EST

Dr. Emil T. Kuriakose M.D. Net Worth



Dr. Emil T. Kuriakose M.D. biography

Dr. Emil T. Kuriakose M.D. is the Chief Medical Officer at Calithera Biosciences Inc.



How old is Dr D?

Dr D is 41, he's been the Chief Medical Officer of Calithera Biosciences Inc since . There are 22 older and no younger executives at Calithera Biosciences Inc. The oldest executive at Calithera Biosciences Inc is H. Ward Wolff, 71, who is the Independent Director.

What's Dr D's mailing address?

Emil's mailing address filed with the SEC is C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD. #200, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Calithera Biosciences Inc

Over the last 10 years, insiders at Calithera Biosciences Inc have traded over $23,150,153 worth of Calithera Biosciences Inc stock and bought 7,859,025 units worth $49,155,939 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Capital Partners Gp, L.L.C...., eDeepika Pakianathan. On average, Calithera Biosciences Inc executives and independent directors trade stock every 43 days with the average trade being worth of $8,053. The most recent stock trade was executed by Deepika Pakianathan on 27 January 2023, trading 121,333 units of CALA stock currently worth $47,320.



What does Calithera Biosciences Inc do?

calithera is focused on discovering and developing first-in-class small molecule drugs that slow tumor growth through controlling key metabolic pathways in the tumor and immune cells. tumor metabolism and tumor immunology are promising new interrelated fields for cancer drug discovery. recent clinical successes have demonstrated the potential to slow abnormal cell growth and create fundamentally new therapies for cancer patients. our investigational onco-metabolism medicines take advantage of the different metabolic requirements of tumor cells and cancer-fighting immune cells. calithera’s discovery and development efforts are focused on solid tumors for which new treatments are urgently needed. we are currently developing our lead candidate in phase 2 trials in patients with renal cell carcinoma, triple negative breast cancer. targeting cancer, differently. our onco-metabolism approach brings an enhanced perspective to cancer.



What does Calithera Biosciences Inc's logo look like?

Calithera Biosciences Inc logo

Calithera Biosciences Inc executives and stock owners

Calithera Biosciences Inc executives and other stock owners filed with the SEC include: